全文获取类型
收费全文 | 1604篇 |
免费 | 116篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 62篇 |
妇产科学 | 22篇 |
基础医学 | 137篇 |
口腔科学 | 33篇 |
临床医学 | 199篇 |
内科学 | 281篇 |
皮肤病学 | 18篇 |
神经病学 | 40篇 |
特种医学 | 243篇 |
外科学 | 92篇 |
综合类 | 33篇 |
一般理论 | 1篇 |
预防医学 | 110篇 |
眼科学 | 9篇 |
药学 | 55篇 |
中国医学 | 5篇 |
肿瘤学 | 381篇 |
出版年
2023年 | 9篇 |
2022年 | 6篇 |
2021年 | 17篇 |
2020年 | 9篇 |
2019年 | 11篇 |
2018年 | 24篇 |
2017年 | 17篇 |
2016年 | 21篇 |
2015年 | 27篇 |
2014年 | 30篇 |
2013年 | 36篇 |
2012年 | 36篇 |
2011年 | 39篇 |
2010年 | 44篇 |
2009年 | 60篇 |
2008年 | 49篇 |
2007年 | 24篇 |
2006年 | 36篇 |
2005年 | 37篇 |
2004年 | 24篇 |
2003年 | 47篇 |
2002年 | 32篇 |
2001年 | 54篇 |
2000年 | 50篇 |
1999年 | 38篇 |
1998年 | 55篇 |
1997年 | 60篇 |
1996年 | 78篇 |
1995年 | 55篇 |
1994年 | 54篇 |
1993年 | 58篇 |
1992年 | 42篇 |
1991年 | 26篇 |
1990年 | 34篇 |
1989年 | 59篇 |
1988年 | 52篇 |
1987年 | 59篇 |
1986年 | 51篇 |
1985年 | 49篇 |
1984年 | 32篇 |
1983年 | 17篇 |
1982年 | 26篇 |
1981年 | 20篇 |
1980年 | 11篇 |
1979年 | 11篇 |
1978年 | 9篇 |
1977年 | 19篇 |
1976年 | 25篇 |
1975年 | 17篇 |
1974年 | 6篇 |
排序方式: 共有1727条查询结果,搜索用时 125 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
N R Ghatak W W Campbell R H Lippman M G Hadfield 《Journal of neuropathology and experimental neurology》1986,45(4):385-395
Morphologic study of the spinal cord of a patient with generalized motor deficits revealed changes in the anterior horns characterized by the selective loss of large motor neurons, gliosis and the abnormal accumulation of 10 nm filaments which appeared as argyrophilic spheroids in the perikarya and axons of motor neurons. The ventral roots were predominantly affected and showed a variable loss of axons. The remaining axons displayed prominent onion-bulb formations, frequent axonal sprouting and occasionally evidence of active demyelination. The coexistence of a demyelinating motor radiculopathy and anterior horn changes simulating those of amyotrophic lateral sclerosis (ALS) may contribute to our understanding of the unresolved question of whether the neuronal perikaryon or its axon is the primary target in the pathogenesis of ALS. These observations also indicate that a rigid separation of pathogenetic mechanisms into neuronopathy, axonopathy and myelinopathy may not be always possible. 相似文献
3.
Olfactory Neuroblastoma and Neuroendocrine Carcinoma of the Anterior Skull Base: Treatment Results at the M.D. Anderson Cancer Center
下载免费PDF全文
![点击此处可从《Skull base》网站下载免费的PDF全文](/ch/ext_images/free.gif)
John R. Austin Hazel Cebrun Mathew M. Kershisnik Adel K. El-Naggar Adam S. Garden Franco DeMonte Lawrence E. Ginsberg Scott M. Lippman Helmuth Goepfert 《Skull base》1996,6(1):1-8
Updated information on the pathologic characterization and treatment of olfactory neurobiastoma (ON) and neuroendocrine carcinoma (NEC) diseases is presented. A series of patients with ON or NEC was evaluated and retrospectively staged using the UCLA system. The parameters evaluated were symptoms, age, sex, risk factor assessment, stage of disease, treatment, and clinical outcome. The median follow-up was 3 years (range, 18 months to 23 years). The predominant therapy (63%) for ON was combined surgery and radiotherapy. Surgery alone or in combination with ancillary treatment was used in 58% of patients with NEC. For the most receat years of the study, patients with NEC have been treated successfully with combined chemotherapy and radiotherapy. Seventy percent of the patients with ON and 75% of the patients with NEC were clinically free of disease during the defined follow-up period. Surgical therapy consisting of a craniofacial resection combined with postoperative radiotherapy has resulted in good local and long-term control of ON. Our experience indicates that combined chemoradiation is an appropriate therapeutic approach for NEC. 相似文献
4.
5.
6.
7.
8.
9.
We have identified a secreted glycoprotein with an apparent molecular weight of 39,000 that is inhibited by estrogens and stimulated by antiestrogens in the MCF-7 human breast cancer cell line. The protein was detected within 24 h of hormone treatment with inhibition occurring at concentrations as low as 10(-11) M estradiol and stimulation occurring with antiestrogens. When phenol red, which has been found to have estrogenic activity, is removed from the tissue culture medium, no inhibition of cell growth or induction of the Mr 39,000 protein is seen with antiestrogens. A 6-fold decrease in the amount secreted in the presence of estrogens is seen under these conditions. The induction was specific in that growth inhibition by several other means did not induce expression of the Mr 39,000 protein. The Mr 39,000 protein has been identified as a glycoprotein complex that can be resolved into four polypeptides with two major components that migrate in the pH range of 5.5 to 6.3 by two-dimensional gel electrophoresis. This protein is the first evidence that estrogens inhibit a specific protein and it may prove useful as a marker of antiestrogen-induced growth arrest in breast cancer. 相似文献
10.